ClinicalTrials.gg
Active, not recruitingNCT06966479Updated May 14, 2026

A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)

A Phase 2 interventional study of Verekitug and Placebo in Severe Asthma, sponsored by Upstream Bio Inc.. Active, not recruiting at 102 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Upstream Bio Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
396
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,695 studies in Asthma with a site in United States — 135 open to participants now, 188 under way, 19 of them phase 3. Asthma · United States.

Enrollment
300th of 1,353
396 · median 100
Started
2025
with 36 others
Phase 2
292 of 1,695
22 open now
Primary completion
2027-09
later than 113 of 183 live
Registered
1,623rd of 1,695
by date

Among the 1,695 studies in Asthma with a site in United States, this one is the 300th largest by enrollment of the 1,353 interventional ones that give a count, is one of 37 that started in 2025, is one of 292 in phase 2, reaches primary completion later than 113 of the 183 other live ones, and was the 1,623rd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

135 of the 1,695 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:

130 more — sign in →

All 135 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,695 studies in Asthma with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate the long-term safety and efficacy of verekitug (UPB-101) in participants who complete the VALIANT study (NCT06196879).

03

Conditions studied

  • Severe Asthma

Keywords

  • UPB-101
  • Verekitug
  • TSLP receptor
  • monoclonal antibody
  • VALIANT
  • VALOUR
  • Respiratory Tract Diseases
  • Bronchial Diseases
  • Asthma
  • Lung Diseases
  • Uncontrolled Asthma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Completion of the VALIANT study (UPB-CP-04 [NCT06196879]) per protocol.
  2. Participant has signed, dated, and received a copy of the Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written form (ICF) for the LTE study.
  3. use by participants must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria

Exclusion Criteria:

  1. Abnormal medical history, physical finding, or safety finding that in the opinion of the Investigator may obscure the study data or interfere with the participant's safety.
  2. Any clinical laboratory test result outside of the reference ranges considered by the Investigator as and that may obscure the study data or interfere with the participant's safety.
  3. Participant with a history or evidence of a clinically significant pulmonary condition (other than asthma), including significant restrictive findings on pulmonary function testing, chronic bronchitis, emphysema, bronchiectasis, pulmonary fibrosis, or any other related condition that may obscure the study data (e.g., gastroesophageal reflux and vocal cord paralysis/dysfunction).
  4. Pregnant or breastfeeding or planning to become pregnant or breastfeed during the study or unwilling to use adequate , if of and sexually active.
  5. Participants with significant protocol deviations in VALIANT, assessed at the discretion of the Sponsor.
  6. Participant is unreliable, incapable of adhering to the protocol and visit schedule according to the judgment of the Investigator or has any disorder that may compromise their ability to give .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
396 participants (actual)

Study arms

  • Experimental
    Verekitug 100 mg Q12W and Placebo

    Participants will receive 0.5 mL of verekitug (100 mg) and 2.0 mL of matching placebo, subcutaneous (SC) injections, every 12 weeks (Q12W) for up to 48 weeks.

    Drug: Verekitug · Drug: Placebo

  • Experimental
    Verekitug 400 mg Q24W and Placebo

    Participants will receive 2.0 mL of verekitug (400 mg) and 0.5 mL of matching placebo, SC injections, at Weeks 24 and 48 visits. Participants will also receive 2.0 mL and 0.5 mL of placebo subcutaneously in two separate injections at Weeks 12 and 36 visits.

    Drug: Verekitug · Drug: Placebo

Interventions

  • Verekitug subcutaneous injection.

    Also known as: UPB-101

  • DrugPlacebo

    Verekitug matching placebo.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: From VALOUR baseline up to Week 64

Secondary outcomes

  1. Annualized Asthma Exacerbation Rate (AAER)

    An asthma exacerbation is defined as a worsening of asthma that required treatment with systemic (oral or intravenous) corticosteroids for at least three consecutive days or a single depo-injectable dose of corticosteroids or an emergency room (ER) or urgent care visit that required systemic corticosteroids or an admission to an inpatient facility and/or evaluation and treatment in a healthcare facility for greater than or equal to 24 hours.

    Time frame: From VALOUR baseline up to Week 60

  2. Change from LTE Baseline in Forced Expiratory Volume in 1 Second (FEV1)

    Spirometry will be performed pre-bronchodilator (BD) to measure lung function. FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration.

    Time frame: From VALOUR baseline to Week 60

  3. Change from LTE Baseline in Fractional Exhaled Nitric Oxide (FeNO)

    Standardized single breath FeNO test is performed to evaluate airway inflammation.

    Time frame: From VALOUR baseline up to Week 60

  4. Change from LTE Baseline in Asthma Control Questionnaire-6 (ACQ-6)

    ACQ-6 is a participant-reported questionnaire to assess asthma control with 6 items assessing night-time waking, symptoms on waking, activity limitation, shortness of breath, wheeze, and rescue short-acting beta agonist use. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The ACQ-6 score is the mean of the responses.

    Time frame: From VALOUR baseline to Week 60

07

Study locations

102 sites
  • Kern Research, Inc.
    Bakersfield, California 93301, United States
  • California Medical Research Associates Inc.
    Northridge, California 91324, United States
  • Integrated Research of Inland Inc
    Upland, California 91786, United States
  • Allergy & Asthma Clinical Research
    Walnut Creek, California 94598, United States
  • Allianz Research Institute
    Westminster, California 92683, United States
  • Advance Pharma Research
    Cutler Bay, Florida 33189, United States
  • Clinical Site Partners, LLC dba Flourish Research
    Miami, Florida 33135, United States
  • Phoenix Medical Research
    Miami, Florida 33165, United States
  • Research Institute of South Florida
    Miami, Florida 33173, United States
  • Health and Life Research Institute, LLC
    Miami, Florida 33176, United States
  • Nouvelle Clinical Research
    Miami, Florida 33189, United States
  • Edward Jenner Research Group, LLC
    Plantation, Florida 33317, United States
  • R&B Medical Center
    Tampa, Florida 33614, United States
  • Clinical Site Partners dba Flourish research
    Winter Park, Florida 32789, United States
  • Treasure Valley Medical Research
    Boise, Idaho 83706, United States
  • Chesapeake Clinical Research Inc
    White Marsh, Maryland 21162, United States
  • Pulmonary Research Institute of Southeast Michigan (PRISM)
    Farmington Hills, Michigan 48336, United States
  • AA MRC
    Flint, Michigan 48504, United States
  • M3 Wake Research
    Las Vegas, Nevada 89106, United States
  • Urban Health Plan INC
    The Bronx, New York 10459, United States
  • Toledo Institute of Clinical Research Inc
    Toledo, Ohio 43617, United States
  • OK Clinical Research, LLC
    Edmond, Oklahoma 73034, United States
  • Horizon Clinical Research
    Cypress, Texas 77429, United States
  • Alina Clinical Trials, LLC
    Dallas, Texas 75209, United States
  • El Paso Pulmonary Association
    El Paso, Texas 79902, United States
  • California Medical Research Associates Inc.
    Houston, Texas 77008, United States
  • Metroplex Pulmonary and Sleep Center Drive
    McKinney, Texas 75069, United States
  • DM Clinical Tomball
    Tomball, Texas 77375, United States
  • Fundacion Cidea
    CABA, Argentina C1121ABE, Argentina
  • Instituto de Medicina Respiratoria, IMeR/ Instituto Médico DAMIC
    Córdoba, Córdoba Province X5003DCE, Argentina
  • Centro de Medicina Respiratoria
    Concepción del Uruguay, Entre Ríos Province E3260, Argentina
  • Fundacion Scherbovsky
    Mendoza, Mendoza Province 5500, Argentina
  • Investigaciones En Patologias Respiratorias
    San Miguel de Tucumán, Tucumán Province CP T4000IAP, Argentina
  • CARE: Centro de Alergia y Enfermedades Respiratorias
    Buenos Aires, C1414AIF, Argentina
  • Investigaciones en Alergias y Enfermedades Respiratorias-InAER
    Buenos Aires, Argentina
  • INSARES
    Mendoza, 5500, Argentina
  • Centro Medico Dharma
    Mendoza, M5500, Argentina
  • Office of Hector H. Altieri MD
    San Miguel de Tucumán, 4000, Argentina
  • Instituto Especialidades de la Salud Rosario
    Santa Fe, 2000, Argentina
  • MHAT "Rahila Angelova" Pernik
    Pernik, Pernik 2300, Bulgaria
  • Ambulatory For Specialized Outpatient Medical Care - Individual Practice - Dr. Nikolay Evgeniev Ruse Ltd
    Rousse, Ruse 7000, Bulgaria
  • Medical Center Excelsior (Todor Popov)
    Sofia, Sofia 1407, Bulgaria
  • MC Convex/DCC Convex
    Sofia, Sofia 1680, Bulgaria
  • Medical Center New Rehabilitation Center EOOD
    Stara Zagora, Stara Zagora 6001, Bulgaria
  • MC Zdrave 1
    Kozloduy, Vratsa 3320, Bulgaria
  • Medical Center HERA EOOD
    Sofia, 1510, Bulgaria
  • Medical center Pulmovizhyn
    Sofia, 1756, Bulgaria
  • Dynamic Drug Advancement
    Ajax, Ontario L1S 2J5, Canada
  • CIMER
    Ñuñoa, Santiago Metropolitan 7770484, Chile
  • Fundacion Medica San Cristobal
    Santiago, Santiago Metropolitan 7630226, Chile
  • Sociedad medica Sy G Limitada
    Providencia, Santiago Metropolitana CHL 7501126, Chile
  • Estudios Clínicos de Enfermedades Respiratorias e Inmunológicas (CIERI)
    Valparaíso, Valparaiso 2531172, Chile
  • Plicni Stredisko Teplice S.R.O
    Teplice, 415 01, Czechia
  • ME Clinical Respiratory Research Hamburg GmbH
    Hamburg, Free and Hanseatic City of Hamburg 22299, Germany
  • RCMS/Lungenpraxis Hohenzollerndamm
    Berlin, Germany 10717, Germany
  • IKF Pneumologie Frankfurt, Clinical Research Center Respiratory Diseases
    Hessen, Germany 60596, Germany
  • POIS Sachsen GmbH
    Leipzig, Germany 04347, Germany
  • KPPK Studienzentrum
    Bendorf, 56170, Germany
  • IKF Pneumologie GmbH & Co. KG
    Mainz, 55128, Germany
  • UOC Pneumologia AOU Renato Dulbecco
    Catanzaro, Catanzaro 88100, Italy
  • Tokyo-Eki Center-building Clinic
    Tokyo, Chuo-ku 103-0027, Japan
  • Oji General Hospital
    Hokkaido, Hokkaido 053-8506, Japan
  • Osaka Habikino Medical Center
    Osaka, Japan 583-8588, Japan
  • Kishiwada City Hospital
    Osaka, Japan 596-8501, Japan
  • National Hospital Organization Ibarakihigashi National Hospital
    Ibaraki, Osaka 319-1113, Japan
  • Osaka Metropolitan University Hospital
    Osaka, Osaka 545-0051, Japan
  • Fukuwa Clinic
    Tokyo, Tokyo 104-0031, Japan
  • Centrum Badan Klinicznych Piotr Napora lekarze Spp
    Wroclaw, Dolnoslaskie Voivodeship 51-162, Poland
  • ALL-MED Specjalistyczna Opieka Medyczna. Medyczny Instytut Badawczy Marek Jutel
    Wroclaw, Dolnoslaskie Voivodeship 53-201, Poland
  • NZOZ J. Małolepszy i Partnerzy
    Wroclaw, Dolnoslaskie Voivodeship 54-239, Poland
  • Centrum Medyczne "All-Med" Badania Kliniczne
    Krakow, Malopolskie Voivodeship 30-033, Poland
  • ATOPIA Niepubliczny Zakład Opieki Zdrowotnej Poradnie Specjalistyczne
    Krakow, Malopolskie Voivodeship 31-141, Poland
  • Małopolskie Centrum Alergologii Spółka z ograniczoną odpowiedzialnością
    Krakow, Malopolskie Voivodeship 31-624, Poland
  • "Alergo-Med" Specjalistyczna Przychodnia Lekarska Spolka Z Ograniczona Odpowiedzialnoscia
    Tarnów, Malopolskie Voivodeship 33-100, Poland
  • Prywatny Gabinet Lekarski Malgorzata Pawlukiewicz
    Rzeszów, Podkarpackie Voivodeship 35-051, Poland
  • Centrum Medycyny Oddechowej, Mroz Spolka Jawna
    Bialystok, Podlaskie Voivodeship 15-044, Poland
  • Uniwersyteckie Centrum Kliniczne, Klinika Alergologii i Pneumonologii
    Gdansk, Pomorskie Voivodeship 80-214, Poland
  • Ostrowieckie Centrum Medyczne spolka cywilna Anna Olech-Cudzik, Krzysztof Cudzik
    Ostrowiec Świętokrzyski, Świętokrzyskie Voivodeship 27-400, Poland
  • Emmed Research
    Pretoria, Gauteng 0002, South Africa
  • Newtown CRC
    Newtown, Johannesburg 2001, South Africa
  • St Augustine's Hospital/Dr. IA Abdullah
    Durban, KwaZulu-Natal 4001, South Africa
  • Synapta Clinical Research Centre
    Durban, KwaZulu-Natal 4001, South Africa
  • Allergy & Immunology Unit, UCT Lung Institute
    Cape Town, Western Cape 7700, South Africa
  • Yeungnam University Hospital
    Daegu, Republic of Korea 42415, South Korea
  • Kyung Hee University Hospital
    Seoul, Republic of Korea 02447, South Korea
  • Seoul National University Hospital
    Seoul, Republic of Korea 03080, South Korea
  • Yonsei University Health System - Severance Hospital
    Seoul, Republic of Korea 03722, South Korea
  • Asan Medical Center
    Seoul, Republic of Korea 05505, South Korea
  • Samsung Medical Center
    Seoul, Republic of Korea 06351, South Korea
  • The Catholic University of Korea, Seoul St. Marys Hospital
    Seoul, Republic of Korea 06591, South Korea
  • Chungbuk National University Hospital
    Taebuk, Republic of Korea 28644, South Korea
  • Eunpyeong St. Marys Hospital
    Seoul, South Korea 03312, South Korea
  • Pectus Respiratory Health
    Barcelona, Catalonia 08017, Spain
  • Hospital Gregorio Marañon
    Madrid, Madrid 28007, Spain
  • Regional Communal Nonprofit Institution "Chernivtsi Regional Clinical Hospital"
    Chernivtsi, Chernivtsi Oblast 58000, Ukraine
  • Municipal Non-Profit Enterprise "Center for Infectious Diseases of the Ivano-Frankivsk Regional Council"
    Ivano-Frankivsk, Ivano-Frankivsk Oblast 76018, Ukraine
  • Castle Hill Hospital, Hull University Teaching Hospitals NHS Trust
    Cottingham, East Yorkshire HU16 5JQ, United Kingdom
  • Gartnavel General Hospital (Glasgow Clinical Research Facility)
    Glasgow, Scotland G12 0YN, United Kingdom
  • Ashford & St Peters Hospital
    Chertsey, Surrey KT16 0PZ, United Kingdom
  • Gannochy Research Suite, Perth Royal Infirmary
    Perth, Tayside PH1 1NX, United Kingdom

Showing the first 100 of 102 sites across 15 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Sep 2027, 28 months after the start.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's planned 28 months is above that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2025
First posted
May 11, 2025
StartActual
May 21, 2025
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06966479
Lead sponsor
Upstream Bio Inc.
Responsible party
Sponsor
First posted
May 11, 2025
Start date
May 21, 2025
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
May 14, 2026

Study contacts

Justin Salciccioli, MD
study director · Upstream Bio

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Verekitug

Start the discussion